Neurology:肾功能受损患者导致中风风险增加,这种亚型尤其要注意!

2022-05-03 MedSci原创 MedSci原创

肾功能损害导致了特定卒中亚型的不同分布和临床效果,在心栓性卒中和小血管闭塞中尤为明显。

慢性肾脏病是一个世界性的公共卫生问题,被认为是中风的既定危险因素。目前仍不清楚它的分布和临床影响在肾功能受损患者的缺血性卒中亚型中是否一致。为此,来自日本福冈医院研究了肾功能损害是否与每种卒中亚型与缺血性卒中总体的比例有关,以及与每种卒中亚型后的功能结果有关,结果发表在Neurology杂志上。

研究参与者为2016年10月至2019年12月期间日本卒中数据库(一个基于医院的多中心卒中登记数据库)登记的10392名急性卒中成年患者,其基线血清肌酐水平或滴定式蛋白尿结果可获得。

所有的缺血性中风都是根据急性中风治疗中的Org 10172试验标准进行分类。不利的功能结果被定义为出院时mRS评分3-6分。混合效应逻辑回归用于确定结果与估计肾小球滤过率(eGFR)、eGFR分层(<45,45-59,≥60 mL/min/1.73 m2)或经协变量调整后的滴速蛋白尿≥1之间的关系。

结果显示,总体而言,2419名(23%)患者的eGFR为45-59 mL/min/1.73 m2,1976名(19%)患者的eGFR<45 mL/min/1.73 m2,包括185名(1.8%)接受血液透析的患者。eGFR 45-59和eGFR<45 mL/min/1.73 m2分别与心源性脑梗风险增加21%和55%(OR=分别为1.21[95% CI,1.05-1.39]和1.55[1.34-1.79])和较低的小血管闭塞风险降低21%和32%(OR=0.79[0.69-0.90]和0.68[0.59-0.79])有关。

在使用eGFR下降作为连续值的分析中,证明与这2种亚型的比例有类似的关联。eGFR<45 mL/min/1.73 m2和蛋白尿都与心源性脑梗(OR=1.30[95% CI,1.01-1.69]和3.18[2.03-4.98])和小血管闭塞(OR=1.44[1.01-2.07]和2.08[1.08-3.98])患者不利的功能结局有关。

综上,肾功能损害导致了特定卒中亚型的不同分布和临床效果,在心栓性卒中和小血管闭塞中尤为明显。

 

参考文献:

Etiology and Outcome of Ischemic Stroke in Patients With Renal Impairment Including Chronic Kidney Disease Japan Stroke Data Bank. Neurology Apr 2022, 98 (17) e1738-e1747; DOI: 10.1212/WNL.0000000000200153

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1850825, encodeId=a78d185082505, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu Jun 30 03:38:52 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739733, encodeId=97c51e397339e, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed Jun 08 14:38:52 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001807, encodeId=6f12200180e24, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 03 05:38:52 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216505, encodeId=56821216505d9, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:37 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216504, encodeId=3e47121650412, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:28 CST 2022, time=2022-05-03, status=1, ipAttribution=)]
    2022-06-30 yese
  2. [GetPortalCommentsPageByObjectIdResponse(id=1850825, encodeId=a78d185082505, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu Jun 30 03:38:52 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739733, encodeId=97c51e397339e, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed Jun 08 14:38:52 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001807, encodeId=6f12200180e24, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 03 05:38:52 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216505, encodeId=56821216505d9, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:37 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216504, encodeId=3e47121650412, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:28 CST 2022, time=2022-05-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1850825, encodeId=a78d185082505, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu Jun 30 03:38:52 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739733, encodeId=97c51e397339e, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed Jun 08 14:38:52 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001807, encodeId=6f12200180e24, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 03 05:38:52 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216505, encodeId=56821216505d9, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:37 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216504, encodeId=3e47121650412, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:28 CST 2022, time=2022-05-03, status=1, ipAttribution=)]
    2022-11-03 yinhl1978
  4. [GetPortalCommentsPageByObjectIdResponse(id=1850825, encodeId=a78d185082505, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu Jun 30 03:38:52 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739733, encodeId=97c51e397339e, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed Jun 08 14:38:52 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001807, encodeId=6f12200180e24, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 03 05:38:52 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216505, encodeId=56821216505d9, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:37 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216504, encodeId=3e47121650412, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:28 CST 2022, time=2022-05-03, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1850825, encodeId=a78d185082505, content=<a href='/topic/show?id=46c682469e4' target=_blank style='color:#2F92EE;'>#肾功能#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82469, encryptionId=46c682469e4, topicName=肾功能)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28d456, createdName=yese, createdTime=Thu Jun 30 03:38:52 CST 2022, time=2022-06-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1739733, encodeId=97c51e397339e, content=<a href='/topic/show?id=ff0c2262459' target=_blank style='color:#2F92EE;'>#中风风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22624, encryptionId=ff0c2262459, topicName=中风风险)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9ba34554146, createdName=1249898am26暂无昵称, createdTime=Wed Jun 08 14:38:52 CST 2022, time=2022-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2001807, encodeId=6f12200180e24, content=<a href='/topic/show?id=d5df12695e6' target=_blank style='color:#2F92EE;'>#Neurol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12695, encryptionId=d5df12695e6, topicName=Neurol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8217292, createdName=yinhl1978, createdTime=Thu Nov 03 05:38:52 CST 2022, time=2022-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216505, encodeId=56821216505d9, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>嗯, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:37 CST 2022, time=2022-05-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1216504, encodeId=3e47121650412, content=<a href='/topic/show?id=8f275032126' target=_blank style='color:#2F92EE;'>#期刊论坛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50321, encryptionId=8f275032126, topicName=期刊论坛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8ba6319857, createdName=1064510_1039, createdTime=Tue May 03 09:45:28 CST 2022, time=2022-05-03, status=1, ipAttribution=)]

相关资讯

Diabetologia:表现为非蛋白尿的肾功能不全的2型糖尿病患者的肾脏结局和全因死亡率

表现为非白蛋白尿的肾功能不全的2型糖尿病患者的肾脏结局和生活预后均比表现为非白蛋白尿的肾功能保留的患者的更差

Haematologica:Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较

在 肾损害(RI) 患者中,将伊萨妥昔单抗 (Isa)添加到地塞米松 (Kd) 中改善了临床结果,并具有可控的安全性,这与在整体 IKEMA 研究人群中观察到的益处一致。

JACC:肾功能轻度受损对接受多血管冠状动脉血运重建手术的患者预后没有影响

在通过PCI或CABG进行血管重建的多血管疾病患者中,肾功能轻度下降与主要综合结果和死亡率的风险增加没有明显关系。

Neurology:肾脏功能不足,可明显增加痴呆的发生率

肾脏功能不足,可明显增加痴呆的发生率

ESC 2020:DAPA-CKD研究:达格列净在慢性肾功能不全患者中的应用

结果表明,在慢性肾脏疾病患者中,无论是否患有2型糖尿病,达格列净明显降低了肾衰竭的风险,减少了心血管死亡或心力衰竭住院治疗的风险,延长了生存期。

Int J Cardiol:肾功能不全患者被忽视!中国急性冠脉综合征临床路径项目新分析

在中国急性冠脉综合征患者中,肾功能不全的患者较少接受指南推荐的治疗策略,其临床预后也较差。

拓展阅读

实战病例看肾功能不全患者的麻醉用药

前不久,他终于下定决心做手术了。然而,本想着这只是老百姓眼中的小手术很简单,但到医院后发现并不是那么回事。

司美格鲁肽对2型糖尿病合并肾功能不全3期临床试验,因疗效优异提前终止(FLOW研究)

2023年10月10日,诺和诺德宣布司美格鲁肽治疗2型糖尿病患者合并肾功能不全的患者的三期临床FLOW由于疗效优异提前终止。IDMC总结了中期数据,疗效达到了特定的预设标准,因此建议停止FLOW临床。

ASN 2022:深度学习模型预测住院成人患者肾功能和血清钾水平

2022年11月3日,在美国肾病周年会上公布一项研究,通过深度学习模型预测成人的肌酐和钾水平方面。

JACC:肾功能轻度受损对接受多血管冠状动脉血运重建手术的患者预后没有影响

在通过PCI或CABG进行血管重建的多血管疾病患者中,肾功能轻度下降与主要综合结果和死亡率的风险增加没有明显关系。

Haematologica:Isatuximab 加卡非佐米和地塞米松与卡非佐米和地塞米松在肾功能不全的复发性多发性骨髓瘤患者中的比较

在 肾损害(RI) 患者中,将伊萨妥昔单抗 (Isa)添加到地塞米松 (Kd) 中改善了临床结果,并具有可控的安全性,这与在整体 IKEMA 研究人群中观察到的益处一致。

Diabetologia:表现为非蛋白尿的肾功能不全的2型糖尿病患者的肾脏结局和全因死亡率

表现为非白蛋白尿的肾功能不全的2型糖尿病患者的肾脏结局和生活预后均比表现为非白蛋白尿的肾功能保留的患者的更差